Product Information
ZYPREXA 5 MG TABLET is a brand product labeled by H2-Pharma LLC, priced at $16.6158 per EA under NDC 61269063130. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Sep 30, 1996. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
H2-Pharma LLCNDC
61269063130
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OLANZAPINEApproval Type
New Drug (NDA)
FDA Application
NDA020592FDA Approved
9/30/1996
TE Code
AB
On Market Since
10/1/1996
Pharmacological Classes
Price Statistics
The NADAC for ZYPREXA 5 MG TABLET has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.6158 per EA |
|---|---|
| All-time high | $16.6819 (Mar 11, 2026) |
| All-time low | $16.6145 (Apr 22, 2026) |
| 52-week high | $16.6819 |
| 52-week low | $16.6145 |
| Median price | $16.6230 |
| Average price | $16.6325 |
| Largest weekly change | -0.2% (Apr 22, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
H2-Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Olanzapine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZYPREXA 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ZYPREXA 5 MG TABLET, manufactured by H2-Pharma LLC, is $16.6158 per EA (NDC 61269063130), effective Sep 30, 2026.
How has the price of ZYPREXA 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ZYPREXA 5 MG TABLET has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for ZYPREXA 5 MG TABLET?
Since Feb 18, 2026, the NADAC for ZYPREXA 5 MG TABLET has ranged from a low of $16.6145 (Apr 22, 2026) to a high of $16.6819 (Mar 11, 2026), with a median of $16.6230 per EA.
Are there cheaper alternatives to ZYPREXA 5 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OLANZAPINE 5 MG TABLET, is $0.0867 per EA — about 99% below ZYPREXA 5 MG TABLET.
Who manufactures ZYPREXA 5 MG TABLET?
ZYPREXA 5 MG TABLET (NDC 61269063130) is labeled by H2-Pharma LLC, and CMS classifies it as a brand product.